Medi-Clear, a UK-based specialist in medication adherence packaging components, has invested in a Nilpeter FB-17 flexo press to support continued growth, innovation capacity, and strengthen efficiency across its healthcare packaging portfolio.

“As our offering continued to evolve and grow with new customers, products and applications, our existing equipment began to limit what we could do,” said Steve Watt, operations and technical director at Medi-Clear. “We needed to invest in new technology to bring capabilities and efficiencies into the business. Our focus areas were throughput and how we handled different materials – and we wanted a solution that would address those properly.”

Medi-Clear selected Nilpeter following a close development process, where the final press specification was shaped and refined as requirements evolved.

“We carefully defined what the right press specifications should look like for us through ideation and iterative testing,” Watt said. “What made Nilpeter stand out was the commitment to the process, and the time, effort, and responsiveness to our requirements, even as they changed. It felt less like a supplier relationship and more like a partnership, and that gave us real confidence that we were building the right bespoke solution.”

With the Nilpeter FB-17, Medi-Clear expects to unlock increased flexibility across its existing formats, while creating a stronger platform for new product development and leaner production.

“This investment gives us opportunities that we simply didn’t have before,” Watt said. “It supports new product development options, and it also allows us to approach our existing portfolio in a leaner way, with improved efficiency and capability.”

John Hammond, Nilpeter UK, who led the engagement, underlined the importance of partnership and trust in projects where a customer’s requirements are highly specific.

“From the beginning, this has been a genuinely collaborative process with Medi-Clear. Their requirements evolved as the specification took shape, and throughout, we focused on transparency and getting the details right. The result is a bespoke FB-17 configuration built on partnership and trust, and a platform designed to support Medi-Clear’s next steps in efficiency and innovation.”

Looking ahead, Medi-Clear sees the FB-17 as an important step in its ongoing focus on performance and capability.

“Our priority now is to see how the press performs in our operation and the value it delivers – we’re confident it will play a meaningful role in supporting our goals,” Watt concluded.